The development of breakthrough products requires a broad array of expertise and resources.  To accelerate Engineered Drug Therapies™ into the clinic and ultimately into the marketplace, Liquidia has partnered with pharmaceutical industry leaders to combine their research and development capabilities with Liquidia’s novel particle design and delivery technology.

Life Science collaborations are focused on utilizing the company’s PRINT technology for the development of novel vaccines and Engineered Drug Therapies™.

To further understand the importance of particle size, shape, and composition on biodistribution and bioavailability, Liquidia has also partnered with researchers at the University of North Carolina-Chapel Hill and other academic institutions to explore these fundamental research questions. Ongoing collaborations with academic and government organizations allow Liquidia to explore multiple areas of current and future research interest. 

To learn more about partnership opportunities, please contact info@liquidia.com.